Nama's AI scorecard currently rates Vericel Buy (7.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is VCEL's P/E ratio?

Vericel trades at a trailing price-to-earnings ratio of 85.3.

When does VCEL report earnings?

Vericel's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.53.

What is the VCEL price target?

The median analyst price target from 7 analysts is $59.00, with a range of $52.00 – $72.00.

Is VCEL Shariah compliant?

Nama's AAOIFI-style screen reads Vericel as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Vericel (VCEL)

Healthcare · Biotechnology · NASDAQ

Vericel (VCEL) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.80B, a trailing price-to-earnings ratio of 85.3 and a free-cash-flow yield of 0.9%. Over the most recent reported fiscal year, revenue grew 16.4%. Nama's AI scorecard rates it Buy, 7.0 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Buy · 7.0/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Middle · +5.1% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-13.3%

How far the last close sits under the highest price of the past five years.

Market cap	$2.80B
Trailing P/E	85.3
Price / book	7.5
Price / sales	9.1
FCF yield	0.9%
Dividend yield	—
Gross margin	74.6%
Operating margin	6.0%
Net margin	7.9%
Revenue growth (YoY)	+16.4%
Revenue growth (3-yr annual)	+18.9%
EPS growth (YoY)	+72.2%
FCF/share growth (YoY)	—
Beta	1.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

VCEL earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.53). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.27	$0.06	+350.0%	—
Q2 2026	Jul 30, 2026	$0.04	-$0.03	+233.3%	$77.46M
Q1 2026	May 7, 2026	-$0.12	-$0.16	+25.0%	$68.42M
Q4 2025	Feb 26, 2026	$0.45	$0.38	+18.4%	$92.92M

VCEL analyst price target

Median target $59.00 from 7 analysts, ranging $52.00 – $72.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live VCEL data on Nama Insights →

VCEL FAQ

Is VCEL a buy?: Nama's AI scorecard currently rates Vericel Buy (7.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is VCEL's P/E ratio?: Vericel trades at a trailing price-to-earnings ratio of 85.3.
When does VCEL report earnings?: Vericel's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.53.
What is the VCEL price target?: The median analyst price target from 7 analysts is $59.00, with a range of $52.00 – $72.00.
Is VCEL Shariah compliant?: Nama's AAOIFI-style screen reads Vericel as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.